Ines P. Da Silva

Blacktown, NSW, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Seasonal variation in immune-related adverse events in advanced cancer patients.

Seasonal variation in immune-related adverse events in advanced cancer patients.

Journal: Cancer immunology, immunotherapy : CII
Published: March 20, 2026

Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients.

Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients.

Journal: Immuno-oncology technology
Published: November 24, 2025

Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma.

Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma.

Journal: Cancer cell international
Published: August 27, 2025

Advances and Future Perspectives for the Management of Non-Small Cell Lung Cancer in Australia: A Narrative Review.

Advances and Future Perspectives for the Management of Non-Small Cell Lung Cancer in Australia: A Narrative Review.

Journal: Asia-Pacific journal of clinical oncology
Published: August 25, 2025

Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.

Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.

Journal: NPJ precision oncology
Published: July 21, 2025

Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1-5 extracranial melanoma oligometastases (AXIOM).

Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1-5 extracranial melanoma oligometastases (AXIOM).

Journal: BMC cancer
Published: July 02, 2025

Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer.

Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 01, 2025

Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.

Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.

Journal: ESMO open
Published: May 28, 2025

GLUT1 expression, lymphocyte distribution and CD3+ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma.

GLUT1 expression, lymphocyte distribution and CD3+ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma.

Journal: Journal of experimental & clinical cancer research : CR
Published: March 13, 2025

Do BRAF-targeted therapies have a role in the era of immunotherapy?

Do BRAF-targeted therapies have a role in the era of immunotherapy?

Journal: ESMO open
Published: March 06, 2025

Long-Term Outcomes and Toxicities in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immunotherapy Containing Regimens.

Long-Term Outcomes and Toxicities in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immunotherapy Containing Regimens.

Journal: Cancer reports (Hoboken, N.J.)
Published: March 04, 2025

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 30, 2025
Showing 1-12 of 36

Last Updated: 09/26/2026